Compared with the control group (CCl4), intravenous injection of SCAP-Ss significantly alleviated the pathological status of hepatic fibrosis by ameliorating the inflammatory infiltration, indicators of liver function (ALT, AST), and liver reconstruction-associated genes (Ck-18, Ck-19, and Hgf). The gene discussed is KRT19; the disease is Hepatic fibrosis.